Attached files
| file | filename |
|---|---|
| EX-4.7 - EX-4.7 - International Stem Cell CORP | isco-ex47_187.htm |
| EX-23.1 - EX-23.1 - International Stem Cell CORP | isco-ex231_8.htm |
| EX-31.1 - EX-31.1 - International Stem Cell CORP | isco-ex311_6.htm |
| EX-31.2 - EX-31.2 - International Stem Cell CORP | isco-ex312_9.htm |
| EX-10.17 - EX-10.17 - International Stem Cell CORP | isco-ex1017_294.htm |
| 10-K - 10-K - International Stem Cell CORP | isco-10k_20201231.htm |
| EX-32.1 - EX-32.1 - International Stem Cell CORP | isco-ex321_11.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of International Stem Cell Corporation (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on March 30, 2021 (the “Report”), I, Sophia Garnette, Vice President, Legal Affairs & Operations of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 30, 2021
|
/s/ Sophia Garnette |
|
Sophia Garnette |
|
Vice President, Legal Affairs & Operations |
|
(Principal Financial Officer) |